08 jun: UBS Racks Up to $350 Million in Losses Related to Facebook IPO -S..
08 jun: Colombian Stocks Decline, Led By Ecopetrol; Peso Weakens
08-06-2012 23:47:00

J&J to Record $600 Million Charge Tied to Outstanding Lawsuits

Relateret indhold
Relateret debat
08 aug - 
We offer fresh cut bank instrument for lease, such as B..

By Ben Fox Rubin

Johnson & Johnson (JNJ) said it plans to record a special charge of roughly $600 million in its second quarter to increase its accrual for potential legal settlements, as it has faced a series of lawsuits over accusations of bribery and improper drug-marketing practices.

The company said the settlement payments stem for a series of outstanding civil cases that involve its drugs Risperdal, Invega and Natrecor, as well as nursing-home pharmacy operator Omnicare Inc. (OCR).

The health-care products company has faced lawsuits related to alleged off-label promotion of its antipsychotic treatment Risperdal, which was once J&J's top-selling drug before generic copycats hit the market, as well as legal challenges over off-label promotion of another schizophrenia treatment, Invega, and the heart-failure drug Natrecor.

Furthermore, the federal government is suing J&J, accusing it of paying kickbacks to induce Omnicare to encourage use of Risperdal and other J&J drugs.

In addition, J&J has dealt with state lawsuits regarding its promotion of Risperdal, including an Arkansas case in which the company in April was ordered to pay $1.2 billion after a jury found that J&J's past marketing of the drug violated the state's consumer-protection laws. J&J previously was ordered to pay $327 million in a South Carolina case and $258 million in Louisiana. The company is appealing all three cases.

In January, J&J agreed to settle a Texas case for $158 million.

Meanwhile, the company agreed to pay an $85 million fine in a criminal case regarding off-label marketing of Natrecor. Parallel civil litigation still hasn't been settled.

The company in April said its first-quarter earnings rose on a foreign-exchange-related gain tied to an acquisition and lower expenses.

Shares closed Friday at $62.98 and were unchanged after hours. The stock is down 4% so far this year.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

(END) Dow Jones Newswires

June 08, 2012 17:47 ET (21:47 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Novo Nordisk køber fabrik i USA

27-08-2014 11:15:10
Novo Nordisk har købt en fabrik i New Hampshire i USA primært med henblik på fremstilling af virksomhedens portefølje af biofarmaceutiske produkter. Sælger er O..

Aktier/tendens: Fokus på Vestas efter kurslussing

27-08-2014 08:30:08
Projektøren peger onsdag fortsat på Vestas efter gårsdagens gevaldige kurslussing, som fulgte i hælene på en negativ analyse fra det amerikanske børshus Bank of..

Novo-konkurrenter sender diabetespille på markedet - GENT

26-08-2014 15:47:10
Diabetesbehandlingspillen Jardiance ( Empagliflozin) kan nu fås på de amerikanske apoteker. Det oplyser medicinalselskaberne Eli Lilly og Boehringer Ingelheim, ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Fokus på Vestas efter kurslussing
2
Tirsdagens aktier: Vraget Vestas trak voldsomt ned - NY
3
Aktier/åbning: Lille oprejsning til Vestas i sløv åbning
4
Novo Nordisk køber fabrik i USA
5
Tirsdagens aktier: Vraget Vestas trak voldsomt ned

Relaterede aktiekurser

Johnson & Johnson 103,44 0,0% Aktiekurs uændret
Omnicare Inc 63,60 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.
Euroinvestor i andre lande: Euroinvestor.com | Euroinvestor.se | Euroinvestor.no | Euroinvestor.fr | Forexinvestor.com| Wisselkoersen.nl | Valuta.se | Valutaveksel.no | Divisas.es | Valute.it
Copyright Euroinvestor A/S 2014  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
27. august 2014 12:51:18
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20140825.1 - EUROWEB7 - 2014-08-27 12:51:18 - 2014-08-27 12:51:18 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x